Cite
Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients.
MLA
Subramanian, Subbaya, et al. “Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients.” Vaccines, vol. 8, no. 2, June 2020, p. 320. EBSCOhost, https://doi.org/10.3390/vaccines8020320.
APA
Subramanian, S., Iles, T., Ikramuddin, S., & Steer, C. J. (2020). Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients. Vaccines, 8(2), 320. https://doi.org/10.3390/vaccines8020320
Chicago
Subramanian, Subbaya, Tinen Iles, Sayeed Ikramuddin, and Clifford J. Steer. 2020. “Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients.” Vaccines 8 (2): 320. doi:10.3390/vaccines8020320.